NCT04960215

Coenzyme Q10 as Treatment for Long Term COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Aarhus University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, placebo-controlled, double-blinded, cross-over designed clinical trial investigating the effect of high-dose Coenzyme Q10 treatment in subjects with persisting symptoms more than 12 weeks af SARS-CoV-2 infection, Long Term COVID-19 (LTC).

Detailed description

The aim is to investigate the effect of high-dose Coenzyme Q10 on number and severity of self-reported symptoms in patients with Long Term COVID-19. The study will be conducted at the Department of Infectious Diseases, Aarhus University Hospital in the LTC Outpatient Clinic. 120 study participants will be randomized 1:1 to receive placebo or CoQ10 in a dose of 500mg/day for 6 weeks. After a wash-out period of 4 weeks, participants are allocated to the opposite treatment for 6 weeks. The EQ-5D-5L and an LTC-specific questionnaire are completed at baseline and after 6,10,16, and 20 weeks. At each of 5 visits blood samples will be collected from the participants for immunological investigations and assessment of cellular metabolism.

Conditions

• Covid19
• Long Term Covid19

Interventions

Type	Name	Description
DRUG	Coenzyme Q10	Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
DRUG	Placebo	A soft gelatin capsule containing soy oil, 5 capsules a day.

Timeline

• Start date: 2021-05-25
• Primary completion: 2022-02-10
• Completion: 2022-02-10
• First posted: 2021-07-13
• Last updated: 2022-05-06

Locations

1 site across 1 country: Denmark